Retina360: Advances in the Management of nAMD is organized by Healio.
Release Date: September 29, 2023
Expiration Date: September 28, 2024
Activity Description:
For patients with neovascular age-related macular degeneration (nAMD), treatment protocols that utilize intravitreal anti-vascular epithelial growth factor (VEGF) therapies in disease management demonstrate significant anatomical and visual acuity benefits. However, the frequency and number of injections needed to maintain initial visual acuity gains with first-generation anti-VEGF therapies can lead to suboptimal visual outcomes due to loss of patient adherence. Second-generation anti-VEGF therapies with extended durations of action along with personalized anti-VEGF treatment protocols seek to address the treatment burden by reducing the frequency of injections while maintaining anatomical and visual outcomes. In this CE monograph, experts in the field guide on how to apply new evidence into practice regarding the efficacy, durability, and safety of approved injectable regimens, while evaluating injectable therapeutic regimens and protocols that can increase adherence to therapy in patients with nAMD.
Learning Objective
Upon successful completion of this activity, participants should be better able to:
• Apply new evidence into practice regarding the efficacy, durability, and safety of injectable regimens approved for use in the treatment of nAMD.
• Incorporate injectable therapeutic regimens and protocols that can increase adherence to therapy in patients with nAMD.